Cargando…

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaye, S. B., Colombo, N., Monk, B. J., Tjulandin, S., Kong, B., Roy, M., Chan, S., Filipczyk-Cisarz, E., Hagberg, H., Vergote, I., Lebedinsky, C., Parekh, T., Santabárbara, P., Park, Y. C., Nieto, A., Poveda, A.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003617/
https://www.ncbi.nlm.nih.gov/pubmed/20643863
http://dx.doi.org/10.1093/annonc/mdq353
_version_ 1782193876494188544
author Kaye, S. B.
Colombo, N.
Monk, B. J.
Tjulandin, S.
Kong, B.
Roy, M.
Chan, S.
Filipczyk-Cisarz, E.
Hagberg, H.
Vergote, I.
Lebedinsky, C.
Parekh, T.
Santabárbara, P.
Park, Y. C.
Nieto, A.
Poveda, A.
author_facet Kaye, S. B.
Colombo, N.
Monk, B. J.
Tjulandin, S.
Kong, B.
Roy, M.
Chan, S.
Filipczyk-Cisarz, E.
Hagberg, H.
Vergote, I.
Lebedinsky, C.
Parekh, T.
Santabárbara, P.
Park, Y. C.
Nieto, A.
Poveda, A.
author_sort Kaye, S. B.
collection PubMed
description Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6–12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. Patients and methods: A detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. Results: Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). Conclusion: The superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these exploratory analyses support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum.
format Text
id pubmed-3003617
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-30036172010-12-20 Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval Kaye, S. B. Colombo, N. Monk, B. J. Tjulandin, S. Kong, B. Roy, M. Chan, S. Filipczyk-Cisarz, E. Hagberg, H. Vergote, I. Lebedinsky, C. Parekh, T. Santabárbara, P. Park, Y. C. Nieto, A. Poveda, A. Ann Oncol Original Articles Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian cancer, particularly in the partially platinum-sensitive subgroup [platinum-free interval (PFI) of 6–12 months]. This superiority has been suggested to be due to the differential impact of subsequent (platinum) therapy. Patients and methods: A detailed analysis of subsequent therapies and survival outcomes in the overall population and in the subsets according to platinum sensitivity was therefore conducted. Results: Similar proportions of patients received subsequent therapy in each arm (76% versus 77%), including further platinum-based regimens (49% versus 55%). Patients in the trabectedin/PLD arm received subsequent chemotherapy at a later time (median delay 2.5 months versus PLD arm). Overall survival from subsequent platinum was significantly prolonged in the partially platinum-sensitive disease subset (hazard ratio = 0.63; P = 0.0357). Conclusion: The superiority of trabectedin/PLD over single-agent PLD in OVA-301 cannot be explained by differences in the extent or nature of subsequent therapies administered to these patients. On the other hand, these exploratory analyses support the hypothesis that the enhanced survival benefits in the partially platinum-sensitive subset might be due to an extended PFI leading to longer survival with subsequent platinum. Oxford University Press 2011-01 2010-07-19 /pmc/articles/PMC3003617/ /pubmed/20643863 http://dx.doi.org/10.1093/annonc/mdq353 Text en © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Kaye, S. B.
Colombo, N.
Monk, B. J.
Tjulandin, S.
Kong, B.
Roy, M.
Chan, S.
Filipczyk-Cisarz, E.
Hagberg, H.
Vergote, I.
Lebedinsky, C.
Parekh, T.
Santabárbara, P.
Park, Y. C.
Nieto, A.
Poveda, A.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title_full Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title_fullStr Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title_full_unstemmed Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title_short Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
title_sort trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003617/
https://www.ncbi.nlm.nih.gov/pubmed/20643863
http://dx.doi.org/10.1093/annonc/mdq353
work_keys_str_mv AT kayesb trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT colombon trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT monkbj trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT tjulandins trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT kongb trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT roym trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT chans trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT filipczykcisarze trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT hagbergh trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT vergotei trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT lebedinskyc trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT parekht trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT santabarbarap trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT parkyc trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT nietoa trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval
AT povedaa trabectedinpluspegylatedliposomaldoxorubicininrelapsedovariancancerdelaysthirdlinechemotherapyandprolongstheplatinumfreeinterval